Epigenetics

22nd September 2010
 NHLI, Kensington, London

The first generation of epigenetic modifying drugs (Histone deacetylase inhibitors and DNA methyl transferase inhibitors) have now reached the market place and are rapidly proving themselves as useful agents for a range of oncology indications. An explosion in the amount of research being carried out in this field is underway with a plethora of new histone and DNA modifying drug targets being pursued for a range of therapeutic indications such as oncology, inflammatory disorders and metabolic disease.

This SMR symposium brings together a panel of international speakers across the breadth of research and development in the field of epigenetics drug discovery, to present and discuss new advances and results from early research to clinical data. Topics include the fundamental biology of epigenetics, therapeutic opportunities and approaches, first generation epigenetic drug case histories in oncology and the next generation of epigenetic drugs.
 

• Download the programme and registration form
• View the programme online
• Register Online